[not BIT specific but I posted this on the PRR thread and someone there requested I post it here too so I assume it's relevant to BIT thread, similar to PRR]
http://www.fool.com/investing/general/2011/10/28/invest-in-biotechs-going-after-unmet-needs.aspx
By Brian Orelli | More Articles
October 28, 2011 | Comments (0)
Wow!
Is there really any other way to describe the launch of Vertex Pharmaceuticals' (Nasdaq: VRTX ) hepatitis C drug Incivek?
We got a first peek at the launch in the second quarter, but that was only six weeks ago. The third quarter offered the first look at a full quarter of revenue. And what a quarter it was: $420 million in net sales of its new hepatitis C drug. Assuming nothing surprising pops up, Incivek will reach the magic $1 billion blockbuster status in its first 12 months on the market. That's easily the most successful launch in recent memory. Dendreon (Nasdaq: DNDN ) , Acorda Therapeutics (Nasdaq: ACOR ) , and Avanir Pharmaceuticals (Nasdaq: AVNR ) could learn a thing or two.
The unmet need of hepatitis C patients is a big reason for the successful launch of Incivek. The current treatments -- Roche's Pegasys and Merck's (NYSE: MRK ) PegIntron -- only cure about half of the patients they treat. Adding Incivek increases that number substantially and allows for a shorter duration of Pegasys or PegIntron, which is helpful given the nasty side effects of those drugs.
Keep in mind that unmet need may be necessary for a launch this successful, but it isn't sufficient to get you there. Incivek still had to post better cure rates than Merck's second-generation drug, Victrelis; if their efficacy had been similar, I'm not sure we'd be drooling over Incivek sales right now. Just look at Human Genome Sciences' (Nasdaq: HGSI ) Benlysta; it's the first new lupus treatment in 50 years, but sales last quarter were just $18.8 million, partially because doctors aren't convinced by the efficacy.
At a market cap topping $8.5 billion, there are still a lot of Incivek sales built in to Vertex's valuation. To grow further, Vertex has to keep growing sales of Incivek and gain approval for its cystic fibrosis drug Kalydeco next. A successful launch of that product would certainly help. But would you expect anything less? Cystic fibrosis is another unmet medical need.
- Forums
- ASX - By Stock
- BIT
- invest in biotechs going after unmet needs
invest in biotechs going after unmet needs
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIT (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.7¢ |
Change
0.001(3.85%) |
Mkt cap ! $24.36M |
Open | High | Low | Value | Volume |
2.7¢ | 2.8¢ | 2.6¢ | $21.78K | 807.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 138461 | 2.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.7¢ | 194761 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 138461 | 0.026 |
10 | 880546 | 0.025 |
2 | 3373333 | 0.024 |
1 | 130000 | 0.023 |
4 | 825000 | 0.022 |
Price($) | Vol. | No. |
---|---|---|
0.027 | 194761 | 1 |
0.028 | 47808 | 2 |
0.029 | 260000 | 2 |
0.030 | 47636 | 2 |
0.031 | 159129 | 3 |
Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |